APLITABART
UNII 4JZ0485VXV

Substance Identification & Data

This profile provides standardized clinical and technical data for Aplitabart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4JZ0485VXV.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2796349-94-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4JZ0485VXV

CAS Registry Number

2796349-94-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

APLITABART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C176625

National Cancer Institute reference terminology for clinical and research data.

INN ID

12990

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Aplitabart

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Aplitabart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Aplitabart

Common Names & Synonyms

Aplitabart [WHO-DD]

Immunoglobulin M, anti-(human death receptor 5) (human-Mus musculus clone IGM-8444 μ-chain), disulfide with human-Mus musculus clone IGM-8444 κ-chain, dimer, pentamer with immunoglobulin [102′′′′′′′′′′′′′′′′′′′′-alanine] human-Mus musculus clone IGM-8444 J chain

aplitabart [INN]

immunoglobulin M-kappa cyclic pentamer bisdisulfide with the JCHAIN (joining chain of multimeric IgA and IgM), anti-[Homo sapiens TNFRSF10B (TNF receptor superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand TRAIL receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262)], humanized monoclonal antibody, monospecific, decavalent, agonist; H-mu heavy chain anti-TNFRSF10B humanized (1-572) [VH (Homo sapiens IGHV3-23*03 (90.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHM*03 (100%) (CH1 (120-223), CH2 (224-335), CH3 (336-441), CH4 (442-552), CHS (553-572)) (120-572)], (133-213')-disulfide with L-kappa light chain anti-TNFRSF10B humanized (1'-213') [V-KAPPA (Homo sapiens IGKV1-13*02 (84.9%) -IGKJ1*01 (100%), CDR-IMGT [6.3.8] (27'-32'.50'-52'.89'-96')) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152'), V101 (190') (107'-213')]; dimer (333-333'':410-410'')-bisdisulfide, 5 [H-mu_L-kappa]2 dimers forming a cyclic pentamer, disulfide 4 x (571''-571), and 1x (571''-15'''':69''''-571)-bisdisulfide with the JCHAIN Y102>A (102'''') (1''''-137''''), produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa

Technical Codes

IGM-8444

IGM8444

External Clinical & Regulatory Resources

Previous UNII4JYR9ZTY2D

Next UNII4JZ2XT4JMN